Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 15/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | DUSP10 | Q9Y6W6 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4896899 | 0.88 | CTSK (0.53) | CTSKPOLBMEN1KMT2A | |
| SCHEMBL4903829 | 0.86 | CTSK (0.64) | CTSK | |
| SCHEMBL4898956 | 0.83 | CTSK (0.60) | CTSKKDM4EPOLBMAPTMEN1 | |
| SCHEMBL5636582 | 0.81 | CTSK (0.62) | CTSKKDM4EPOLBMAPTMEN1 | |
| SCHEMBL4907382 | 0.80 | CTSK (0.56) | CTSKPOLB | |
| SCHEMBL4900920 | 0.79 | CTSK (0.57) | CTSK | |
| SCHEMBL4904038 | 0.79 | CTSK (0.57) | CTSK | |
| SCHEMBL4900925 | 0.79 | CTSK (0.57) | CTSKPOLBMEN1KMT2A | |
| SCHEMBL4904640 | 0.79 | CTSK (0.63) | CTSKPOLB | |
| SCHEMBL14260310 | 0.78 | CTSK (0.78) | CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080058333-A1 | CYCLOALKYL KETOAMIDES DERIVATIVES USEFUL AS CATHEPSIN K INHIBITORS | CATALANO JOHN G | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058333-A1 | CYCLOALKYL KETOAMIDES DERIVATIVES USEFUL AS CATHEPSIN K INHIBITORS | CTSK, CTSS, CTSE | CTSK 1/4885KDM4E 466/4885POLB 2328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.